A strong management team and sound investment process underpin BlackRock Health Sciences Opps Inv C's Morningstar Quantitative Rating of Bronze. Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the highest quintile among peers.
- NAV / 1-Day Return 53.90 / 0.61 %
- Total Assets 9.1 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.840%
- Distribution Fee Level Below Average
- Share Class Type Level Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 0.00
- Turnover 51%
Morningstar’s Analysis SHSCX
Will SHSCX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.